Bexagliflozin

Overview

Bexagliflozin (EGT1442) is an orally active and selective SGLT2 inhibitor with IC 50 values of 0.002 μM and 5.6 μM for SGLT2 and SGLT1 , respectively. Bexagliflozin selectively inhibits SGLT2 -mediated sodium-dependent glucose uptake. Bexagliflozin induces saturable urinary glucose excretion in normal rats and dogs. Bexagliflozin reduces blood glucose and HbA 1c levels in db/db mice without affecting body mass or insulin level. Bexagliflozin can be used for the research of type 2 diabetes mellitus, hypertensive stroke.

Application

Products | Products > Disease Areas > Metabolic or Endocrine Disease | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Disease Areas > Glucose Metabolism | Products > Disease Areas > Type 2 Diabetes | Products > Signaling Pathways > Membrane Transporter/Ion Channel | Products > Research Areas > Metabolic Disease | Products > Research Areas > Cardiovascular Disease | Products > Signaling Pathways > SGLT

Product Information

• Catalog No.: HY-17604
• CAS No.: 1118567-05-7
• Molecular Formula: C24H29ClO7
• Molecular Weight: 464.94
• Purity: 98.81%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Solubility: ≥ 3 mg/mL (6.45 mM); Clear solution
• Availability: In-stock

Source

Original product source